Darwin AG, a European healthcare company specializing in human genetics and personalized products, has officially changed its name to Novogenia AG following the registration of the corresponding amendment to the Articles of Association in the Commercial Register. The name change, approved at the Annual General Meeting on June 26, 2026, reflects the company's strategic focus on its core operating brand, Novogenia GmbH, and aims to unify its market presence across customers, business partners, investors, and the broader community.
Novogenia GmbH, the wholly owned subsidiary driving the group's operational business and future growth, has been active in human genetics for many years, developing and selling personalized products based on genetic analysis. The Novogenia brand is recognized for its scientific expertise and technological innovation. By renaming the parent company to Novogenia AG, the group seeks to simplify its corporate structure, streamline communication, and create a consistent image across all target groups, including the capital market.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, stated, “Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market.”
The name change has no impact on the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. The company, now Novogenia AG, continues to be listed under ISIN DE000A3C35W0.
This rebranding is significant for the industry as it signals a consolidation of brand identity in the competitive personalized healthcare market. By aligning the corporate name with its operational brand, Novogenia AG strengthens its position as a leading provider of genetic analysis-based products, including diagnostics, treatments, preventive measures, and customized nutritional supplements and cosmetics. The move is expected to enhance brand recognition and trust among consumers and investors alike, potentially driving further growth in the longevity and personalized medicine sectors.
For more information about Novogenia AG and its services, visit https://novogenia.com/novogenia-ag.
